Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2beta-Thalassemia 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 27fludarabine 26Cyclophosphamide 25Specimen Handling 21Azacitidine 20Biopsy 15Whole-Body Irradiation 14Stem Cell Transplantation 13Decitabine 13Cytarabine 13Tacrolimus 12Melphalan 12fludarabine phosphate 11Mycophenolic Acid 11Busulfan 11Injections 8X-Rays 7Thiotepa 7Hematopoietic Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7decitabine and cedazuridine drug combination 6Cyclosporine 6ruxolitinib 5Magnetic Resonance Spectroscopy 5Idarubicin 5Filgrastim 5gilteritinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Myelodysplastic Syndromes × luspatercept × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡